UBS Likes Pfizer's MTSR Obesity Deal but Stays Neutral on PFE [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
On January 7, UBS initiated coverage of Pfizer Inc. (NYSE:PFE) with a Neutral rating and a $25 price target. The firm pointed to lingering uncertainty around Pfizer's revenue outlook, with roughly $15 billion to $20 billion tied to major drugs expected to lose patient exclusivity over the next three years. UBS said it likes the recent MTSR obesity deal, but added that Pfizer still needs additional moves to reduce the longer-term 2028 LOE risk. A day later, Pfizer Inc. (NYSE:PFE) announced a new AI-focused partnership. On January 8, the company said it has entered a strategic collaboration with Boltz, PBC, an applied AI research lab, to expand the use of biomolecular AI models and generative workflows across Pfizer's R&D teams. The aim is to help scientists move faster in designing both small-molecule medicines and biologics. Boltz is known for its open-source biomolecular foundation models, including Boltz-2 and BoltzGen, which are widely used in the pharmaceutical industry for p
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapy [Yahoo! Finance]Yahoo! Finance
- Down 55%, Should You Buy the Dip on Pfizer? [Yahoo! Finance]Yahoo! Finance
- MoneyShow's Best Investment Ideas For 2026: Part 7 [Seeking Alpha]Seeking Alpha
- Could Pfizer Inc.'s (NYSE:PFE) Weak Financials Mean That The Market Could Correct Its Share Price? [Yahoo! Finance]Yahoo! Finance
- Pfizer (PFE) CEO Isn't Ready For A Fight With RFK Jr., Says Jim Cramer [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 11/4/25 - Beat
PFE
Sec Filings
- 1/16/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- PFE's page on the SEC website